Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680521 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
A Phase 2 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT03680521 is a Phase 2 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT03680521, a Phase 2 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The study will evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in the neoadjuvant setting prior to nephrectomy.
Interventions
- DRUG Nivolumab
- DRUG Sitravatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-10-10 |
| Est. Completion | 2023-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03680521
The ClinicalTrials.gov registry entry for NCT03680521 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03680521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03680521 about?
NCT03680521 is a clinical study titled "Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma". The study will evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in the neoadjuvant setting prior to nephrectomy.
What is the current status of trial NCT03680521?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2018-10-10. Estimated completion is 2023-05-18.
What interventions are being tested in trial NCT03680521?
The interventions under investigation include: Nivolumab (DRUG), Sitravatinib (DRUG).
Who is sponsoring clinical trial NCT03680521?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.